Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05853419

Change History and Adopt a Robotic SolutioN for anGioplasty procedurE

The main objective of the CHANGE registry is the evaluation of the real-world performance and safety profile of the R-One System in PCI.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–120 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Het Ziekenhuisnetwerk Antwerpen vzw, Antwerp, Belgium

Loading trial locations.

About this study

The R-One system is a class "IIb" CE marked medical device designed to remote deliver and manipulate coronary guidewires and stent/balloon devices during Percutaneous Coronary Intervention (PCI). The system comprises the R-One Robotic Platform used in combination with two accessories, the Mobile Radioprotection Screen and a sterile and single-use R-One Consumable Kit. The R-One is not autonomous and operates only under the operator's commands.

This study is a single-arm, open-label, multi-center registry.

The CHANGE registry, part of the ROBOCATH's post-market clinical follow-up activities, is a real world study aiming to confirm the safety and performance, including the clinical benefit, of the R-One robotic systems medical device.

500 patients with coronary artery disease and with clinical indication for PCI will be recruited in up to Up to 15 centers distributed in Europe and South Africa.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Age ≥ 18 years;
  • 2.Subjects with coronary artery disease with clinical indication for PCI;
  • 3.Subject deemed appropriate for robotic-assisted PCI; and
  • 4.The subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent.

Exclusion criteria

  • 1.Failure/inability/unwillingness to provide informed consent, unless the ethic committee has waived informed consent; or
  • 2.The Investigator determines that the subject or the coronary anatomy is not suitable for robotic-assisted PCI.
  • 3.STEMI
  • 4.Cardiogenic shock
  • 5.Subjects will not be included if they are under judicial protection, guardianship or curatorship or if they are deprived of their liberty by judicial or administrative decision.

Treatment and study plan

Robotic-assisted PCI

Device

Robotic-assisted PCI will be performed according to the routine hospital practices, current scientific guidelines and following Instructions for Use (IFU) provided by the manufacturer

Primary outcomes

  1. Clinical success

    Time frame: From Day 0 to Day 3

    Less than 30% residual stenosis (visual estimate) post PCI in the lesion(s) treated with the R-One System, without in-hospital major adverse cardiac events (MACE).

  2. Technical success

    Time frame: During procedure

    Absence of any unplanned manual assistance or conversion to manual PCI for procedural completion

Secondary outcomes

  1. Radiation exposure for the patient

    Time frame: During procedure

    Dose (DSP and Air Kerma) measured by the imaging system during the procedure.

  2. Overall Procedure Time

    Time frame: During procedure

    Defined as the time measured from the insertion of the hemostasis sheath until the removal of the guide catheter.

  3. Overall contrast volume

    Time frame: During procedure

    Total volume of contrast (mL) used during the procedure.

  4. Radiation exposure for the operator

    Time frame: During procedure

    Cumulative dose the operator receives as recorded from an electronic pocket dosimeter during the procedure.

  5. Fluoroscopy Time

    Time frame: During procedure

    Total fluoroscopy utilized during the procedure as recorded by an Imaging System.

  6. Safety event occurrence

    Time frame: From Day 0 to Day 3

    Medical device's safety event occurrence

Study contacts

Contact information is provided by the study sponsor or research team.

Hamouda Abassi, PhD

CONTACT

[email protected]

+33 2 32 10 67 42

Sponsors and collaborators

Lead sponsor

Robocath

Industry

Collaborators

  • European Cardiovascular Research Center

Registry information

Acronym: CHANGE

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
May 10, 2023
Registry last updated
Aug 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.